BRYAN HAUGEN

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. ncbi request reprint Management of the patient with progressive radioiodine non-responsive disease
    B R Haugen
    Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA
    Semin Surg Oncol 16:34-41. 1999
  2. ncbi request reprint Retinoid X receptor gamma-deficient mice have increased skeletal muscle lipoprotein lipase activity and less weight gain when fed a high-fat diet
    Bryan R Haugen
    Division of Endocrinology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Endocrinology 145:3679-85. 2004
  3. ncbi request reprint Redifferentiation therapy in advanced thyroid cancer
    Bryan R Haugen
    University of Colorado Health Sciences Center, B151, 4200 E 9 Ave, Denver 80262, USA
    Curr Drug Targets Immune Endocr Metabol Disord 4:175-80. 2004
  4. ncbi request reprint Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumours
    Bryan R Haugen
    Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Clin Endocrinol (Oxf) 56:281-90. 2002
  5. ncbi request reprint Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin
    Bryan R Haugen
    Department of Medicine, Division of Endocrinology, University of Colorado Health Sciences Center, Denver, USA
    Thyroid 12:37-43. 2002
  6. ncbi request reprint Initial treatment of differentiated thyroid carcinoma
    B R Haugen
    University of Colorado Health Sciences Center, B151, 4200 East 9th Avenue, Denver, CO 80262, USA
    Rev Endocr Metab Disord 1:139-45. 2000
  7. doi request reprint In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma
    Joshua P Klopper
    Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045, USA
    Clin Cancer Res 14:589-96. 2008
  8. ncbi request reprint Outcomes of patients with differentiated thyroid carcinoma following initial therapy
    Jacqueline Jonklaas
    Georgetown University Medical Center, Washington, DC 20007, USA
    Thyroid 16:1229-42. 2006
  9. pmc Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue
    Lewis M Brown
    Department of Pediatrics, Section of Pulmonary Medicine, The University of Colorado at Denver and Health Sciences Center, Aurora, 80045, USA
    Mol Carcinog 45:613-26. 2006
  10. ncbi request reprint Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal
    Heribert Hänscheid
    Klinik und Poliklinik fur Nuklearmedizin, Universitat Wurzburg, D 97080 Wurzburg, Germany
    J Nucl Med 47:648-54. 2006

Research Grants

Collaborators

Detail Information

Publications27

  1. ncbi request reprint Management of the patient with progressive radioiodine non-responsive disease
    B R Haugen
    Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA
    Semin Surg Oncol 16:34-41. 1999
    ..Chemotherapy may prove useful not only as a tumoricidal agent but as therapy for tumor re-differentiation in preparation for radioiodine therapy...
  2. ncbi request reprint Retinoid X receptor gamma-deficient mice have increased skeletal muscle lipoprotein lipase activity and less weight gain when fed a high-fat diet
    Bryan R Haugen
    Division of Endocrinology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Endocrinology 145:3679-85. 2004
    ..An understanding of the mechanisms governing the role of RXR in TG disposal and metabolism may lead to the rational design of RXR-selective agonists and antagonists that may be useful in common disorders such as dyslipidemia and obesity...
  3. ncbi request reprint Redifferentiation therapy in advanced thyroid cancer
    Bryan R Haugen
    University of Colorado Health Sciences Center, B151, 4200 E 9 Ave, Denver 80262, USA
    Curr Drug Targets Immune Endocr Metabol Disord 4:175-80. 2004
    ..Development of these and other novel agents for the treatment of advanced thyroid cancer is critical for us to treat an uncommon progression of a common malignancy...
  4. ncbi request reprint Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumours
    Bryan R Haugen
    Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Clin Endocrinol (Oxf) 56:281-90. 2002
  5. ncbi request reprint Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin
    Bryan R Haugen
    Department of Medicine, Division of Endocrinology, University of Colorado Health Sciences Center, Denver, USA
    Thyroid 12:37-43. 2002
    ..In our practice, an rhTSH-stimulated Tg greater than 4-5 ng/mL often resulted in further evaluation, while a Tg less than 4 ng/mL rarely resulted in further immediate evaluation...
  6. ncbi request reprint Initial treatment of differentiated thyroid carcinoma
    B R Haugen
    University of Colorado Health Sciences Center, B151, 4200 East 9th Avenue, Denver, CO 80262, USA
    Rev Endocr Metab Disord 1:139-45. 2000
    ..In this review, we have hopefully distilled much of that information into a proposed current therapeutic approach to individual patients with differentiated thyroid cancer...
  7. doi request reprint In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma
    Joshua P Klopper
    Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045, USA
    Clin Cancer Res 14:589-96. 2008
    ..Additionally, we explore potential mediators of the rexinoid effect on a responsive anaplastic thyroid cancer using comparative microarray analysis...
  8. ncbi request reprint Outcomes of patients with differentiated thyroid carcinoma following initial therapy
    Jacqueline Jonklaas
    Georgetown University Medical Center, Washington, DC 20007, USA
    Thyroid 16:1229-42. 2006
    ..We were unable to show any impact, positive or negative, of specific therapies in stage I patients...
  9. pmc Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue
    Lewis M Brown
    Department of Pediatrics, Section of Pulmonary Medicine, The University of Colorado at Denver and Health Sciences Center, Aurora, 80045, USA
    Mol Carcinog 45:613-26. 2006
    ..Many of the differences observed would not have been detected by genomic or other proteomic approaches...
  10. ncbi request reprint Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal
    Heribert Hänscheid
    Klinik und Poliklinik fur Nuklearmedizin, Universitat Wurzburg, D 97080 Wurzburg, Germany
    J Nucl Med 47:648-54. 2006
    ..7 GBq (131)I in differentiated thyroid cancer after stimulation with recombinant human TSH (rhTSH) or by thyroid hormone withdrawal (THW) are presented...
  11. ncbi request reprint A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal
    Pamela R Schroeder
    Johns Hopkins Medical Institutions, Division of Endocrinology and Metabolism, 1830 East Monument Street, Suite 333, Baltimore, Maryland 21287, USA
    J Clin Endocrinol Metab 91:878-84. 2006
    ..Levothyroxine (L-T4) withdrawal for thyroglobulin measurement and whole body scanning increases these tests' sensitivities but causes hypothyroidism. Recombinant human TSH (rhTSH) enables testing without L-T4 withdrawal...
  12. ncbi request reprint Effects of rexinoids on thyrotrope function and the hypothalamic-pituitary-thyroid axis
    Vibha Sharma
    Division of Endocrinology, Metabolism, and Diabetes, University of Colorado at Denver and Health Sciences Center, MS 8106, P O Box 6511, Aurora, Colorado 80045, USA
    Endocrinology 147:1438-51. 2006
    ..Rexinoids also stimulate type 1 iodothyronine deiodinase activity in the liver and pituitary...
  13. ncbi request reprint Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects
    Wendy M Golden
    Division of Endocrinology, Metabolism, and Diabetes, University of Colorado at Denver and Health Sciences Center, Building RC 1 South Tower, MS 8106 12801 East 17th Avenue, PO Box 6511, Aurora, Colorado 80045, USA
    J Clin Endocrinol Metab 92:124-30. 2007
    ..The influence of rexinoids on thyroid function in healthy subjects is not clear...
  14. ncbi request reprint Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment
    Joshua P Klopper
    Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado Cancer Center, University of Colorado Health Sciences Center, Box B151, 4200 East 9th Avenue, Denver, CO 80262, USA
    Mol Cancer Ther 3:1011-20. 2004
    ..Additionally, expression of both RXRgamma and PPARgamma may be necessary for maximal growth inhibition by ligands and may be required for the increased apoptosis...
  15. ncbi request reprint Patients with differentiated thyroid carcinoma benefit from radioiodine remnant ablation
    Bryan R Haugen
    J Clin Endocrinol Metab 89:3665-7. 2004
  16. ncbi request reprint Excessive survivin expression in thyroid lymphomas
    Masahiro Sugawara
    Division of Endocrinology and Metabolism, Molecular Pathology Division, Department of Pathology and Laboratory Medicine, Greater Los Angeles Veteran s Affairs Medical Center and UCLA School of Medicine, 90073, USA
    Hum Pathol 33:524-7. 2002
    ..Our study shows that measuring survivin mRNA levels or immunohistochemistry of the protein expression can be useful to aid the diagnosis of thyroid lymphoma when histologic diagnosis is difficult...
  17. ncbi request reprint Isolation and functional analysis of the mouse RXRgamma1 gene promoter in anterior pituitary cells
    Nicole B McDermott
    Department of Medicine, University of Colorado Health Sciences Center, University of Colorado Cancer Center, Denver, Colorado 80262, USA
    J Biol Chem 277:36839-44. 2002
    ..Isolation and characterization of the mouse RXRgamma1 promoter region provides a tool for further investigation focusing on thyrotrope-specific gene expression as well as negative regulation of genes by retinoic acid...
  18. ncbi request reprint Congenital isolated central hypothyroidism caused by a "hot spot" mutation in the thyrotropin-beta gene
    Michael T McDermott
    Division of Endocrinology, Metabolism and Diabetes, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Thyroid 12:1141-6. 2002
    ..quot;..
  19. ncbi request reprint Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids
    Bryan R Haugen
    Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Cancer Center, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Clin Endocrinol Metab 89:272-80. 2004
    ..In summary, we identified the RARbeta and RXRgamma isoform to be differentially expressed in thyroid cancer cell lines and tumor tissue. These isoforms seem to predict response to retinoid therapy in thyroid cancer cell lines...
  20. ncbi request reprint The management of subclinical hyperthyroidism by thyroid specialists
    Michael T McDermott
    Division of Endocrinology, Metabolism and Diabetes, and Division of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, Denver, Colorado 80010, USA
    Thyroid 13:1133-9. 2003
    ..In the absence of adequate evidence-based guidelines, it is hoped that this survey of expert opinions may provide useful guidance for physicians providing care for patients with subclinical hyperthyroidism...
  21. ncbi request reprint Uses for recombinant human TSH in patients with thyroid cancer and nodular goiter
    Whitney W Woodmansee
    University of Colorado Health Sciences Center, Denver, Colorado, USA
    Clin Endocrinol (Oxf) 61:163-73. 2004
    ..The diagnostic and therapeutic role of rhTSH in patients with differentiated thyroid cancer and nodular goiter will be discussed in this review...
  22. pmc Expanding indications for recombinant human TSH in thyroid cancer
    Bryan R Haugen
    Thyroid 18:687-94. 2008
  23. ncbi request reprint Management guidelines for patients with thyroid nodules and differentiated thyroid cancer
    David S Cooper
    Sinai Hospital of Baltimore and Johns Hopkins University School of Medicine, MD, USA
    Thyroid 16:109-42. 2006
  24. ncbi request reprint Tumor-specific changes in mtDNA content in human cancer
    Elizabeth Mambo
    Department of Otolaryngology Head and Neck Surgery, Head and Neck Cancer Research Division, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Int J Cancer 116:920-4. 2005
    ..Our findings suggest that mtDNA content can be used as a molecular diagnostic tool to help identify genetic abnormalities in human tumors...
  25. ncbi request reprint The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer
    Katie B Weber
    Department of Medicine, University of Colorado Health Sciences Center, Denver, USA
    Am J Clin Pathol 122:524-31. 2004
    ..TPO alone is not adequately sensitive for the evaluation of any thyroid lesion. The combination of galectin-3 and TPO is complementary as a diagnostic and prognostic tool for patients with papillary carcinoma...
  26. ncbi request reprint Correlation of survivin mRNA detection with histologic diagnosis in normal endometrium and endometrial carcinoma
    Rainer Lehner
    Department of Pathology, University of Colorado Health Sciences Center, East Ninth Avenue, Denver, Colarado, USA
    Acta Obstet Gynecol Scand 81:162-7. 2002
    ..The objective of this study was to determine if survivin mRNA expression is a marker of endometrioid adenocarcinoma and if survivin mRNA levels correlate with tumor grade and stage...
  27. doi request reprint Discovery and validation of protein abundance differences between follicular thyroid neoplasms
    Romana T Netea-Maier
    Department of Endocrinology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Cancer Res 68:1572-80. 2008
    ..Three of these were validated by immunohistochemistry. These findings provide further insights into the diagnosis, prognosis, and pathophysiology of follicular-derived thyroid neoplasms...

Research Grants11

  1. ROLE OF RETINOIDS AND RECEPTORS IN THYROTROPE FUNCTION
    BRYAN HAUGEN; Fiscal Year: 2004
    ....
  2. Thiazolidinediones as Thyroid Cancer Therapy
    BRYAN HAUGEN; Fiscal Year: 2009
    ....